Josh Siegfried

PHD Doctor of Philosophy,  Toronto General - University Health Network 

Location: Germany

Consulting Services

Biostatistics Admin and Customer Support Pharma-CRO-Device Career Advice and Mentoring

Areas Of Interest

U4 U6 Small Nuclear Ribonucleoproteins Tactual Performance Test Mastocytosis, Diffuse Cutaneous Todrazoline Colletotrichums Nerve Growth Factor-inducible B Protein Cyclopentadienes Hyphochytrium Roxigamma Treatment, Radiation Peroxidase-Labeled Antibody Technique EC-VMFa Renal-Type Arginine Vasopressin Receptor Advertisements B Antigens, Anti-Hepatitis SR 33589B Abortions, Saline-Solution Volleyball Black Flies Surgical Injury Dilevalol Esophagus Neoplasm Left-Right Determination Factors Semaphorin 2 Class II Phosphatidylinositol 3 Kinases Cervical Tuberculous Lymphadenitis Complement Component 4 Solitary Functioning Kidney Apo 2 Ligand Tyrosyl tRNA Synthetase Interleukin 18 Receptor 1 Tuberculosis Societies Chemokine CXCL12 Protein Interaction Mapping One Carbon Group Transferases Idiopathic Facial Paralyses Tendonopathy Furrow Keratitis

Professional Narrative

Dr. Josh Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.

Employment

Executive Director, Harvard Med 2018
Director Medicine, Harvard Med 1993

Education

Doctor of medicine, Perelman School of Medicine 2017
Doctor of medicine, Weill Medical College 1987

Referees

Publications

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell Stem Cell. 2016 Jan 7;18(1):25-38. doi: 10.1016/j.stem.2015.12.005. PMID: 26748754; PMCID: PMC4728053.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :

Languages

Language Proficiency :

Translation Services :

Serving Millions of physicians and biomedical scientists in Industry and academia.

Site
Services
Follow Us
Contact Us
  • support@scienceandminds.com

Copyright © 2025 Trialect Inc. All rights reserved. | v2023.06.17.02